The purpose of this Funding Opportunity Announcement (FOA) is to fill gaps in our understanding of (a) the impact of substance abuse on HIV, HIV/HCV co-infection associated disease progression, (b) the pathogenic interactions between HIV and hepatitis C virus, (c) hepatic and non-hepatic co-morbidities associated with HIV/HCV-co-infections in people with substance abuse disorders (SUDs), and (d) the effectiveness of interferon-free direct acting antiviral (DAAs) drug regimens to treat HIV/HCV co-infections in people with SUDs. This FOA is informed by priority area in the NIH HIV/AIDS Research Priorities and Guidelines for Determining AIDS Funding: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html and the HHS National Viral Hepatitis Action Plan 2017-2020: https://www.hhs.gov/hepatitis/blog/2017/01/19/updated-national-viral-hepatitis-action-plan-2017-2020.html

The Office of Naval Research (ONR) is interested in receiving proposals for its Young Investigator Program (YIP). ONR's Young Investigator Program (YIP) seeks to identify and support academic scientists and engineers who are in their first or second full-time tenure-track or tenure-track-equivalent academic appointment, have begun their first appointment on or after 31 December 2012, and who show exceptional promise for doing creative research. The objectives of this program are to attract outstanding faculty members of Institutions of Higher Education (hereafter also called "universities") to the Department of the Navy's Science and Technology (S&T) research program, to support their research, and to encourage their teaching and research careers. Proposals addressing research areas (as described in the ONR Science and Technology Department section of ONR's website at www.onr.navy.mil) which are of interest to ONR program officers will be considered. Contact information for each division (a subgroup of an S&T Department) is also listed within the S&T section of the website

The purpose of this Funding Opportunity Announcement (FOA) is to support exploratory basic research to develop innovative phylodynamic approaches to identify and prioritize the most rapidly growing HIV transmission clusters within a given population of individuals in near-real time. 

The purpose of this Funding Opportunity Announcement (FOA) is to support the development of imaging approaches to identify and characterize persistent HIV reservoirs in patients undergoing suppressive antiretroviral therapy (ART) and to quantify the nature and size of these reservoirs in response to therapeutic interventions.

The purpose of this Funding Opportunity Announcement (FOA) is to support exploratory basic research to develop innovative phylodynamic approaches to identify and prioritize the most rapidly growing HIV transmission clusters within a given population of individuals in near-real time.

NIST is soliciting applications from eligible institutions of higher education in the U.S. and its territories that offer two- or four- year degrees in academic science, technology, engineering and mathematics (STEM) disciplines, which include but are not limited to biochemistry, biological sciences, chemistry, computer science, engineering, electronics, materials science, mathematics, nanoscale science, neutron science, physical sciences, physics, and statistics, to establish and manage a program to support collaborative research relationships among NIST staff, undergraduate and graduate students, individuals with bachelor's or master's degrees, post-doctoral fellows, and academic affiliates, and the PREP researchers' academic institutions. These collaborative relationships will include research opportunities at the relevant NIST campuses in Boulder, Colorado (CO) (PREP Boulder), or Gaithersburg, Maryland (MD), and/or Charleston, South Carolina (SC) (PREP Gaithersburg). Eligible applicants may apply to establish and manage a PREP Boulder program or a PREP Gaithersburg program or may apply to establish and manage programs for both.

The SBIR program, as established by law, is intended to meet the following goals: stimulate technological innovation in the private sector; strengthen the role of small business in meeting Federal research or research and development (R/R&D) needs; increase the commercial application of Federally-supported research results; foster and encourage participation by socially and economically disadvantaged small business concerns and women-owned business concerns in the SBIR program; and improve the return on investment from Federally-funded research for economic and social benefits to the Nation.

The Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD) is organized into five Joint Project Management Offices (JPMO), each responsible for specific commodity areas. General information on the JPEO-CBD and subordinate JPMOs can be obtained from the JPEO-CBD website at http://www.jpeocbd.osd.mil/. The medical CBRN countermeasures developed by the Joint Project Manager Medical Countermeasure Systems (JPM MCS) office directly support the current, near-term, and far-term challenges by providing the capability to prevent, diagnose and treat the effects of chemical, radiological and biological warfare agents. Mission areas and technical points of contact for the product management offices within the JPM MCS are shown in Section VII of this BAA. Proposals are sought from all eligible sources as specified herein, including educational institutions, nonprofit organizations, and private industry. This Broad Agency Announcement (BAA) provides general information, proposal preparation instructions, evaluation and selection criteria, and award administration.

The Alzheimer's Drug Discovery Foundation, in partnership with the Association for Frontotemporal Degeneration, has issued a Request for Proposals designed to accelerate and support innovative drug discovery programs for FTD, a disease process that results in progressive damage to the temporal and/or frontal lobes of the brain.

The Histiocytosis Association is a global nonprofit organization dedicated to addressing the unique needs of patients and families dealing with the effects of histiocytic disorders, a group of diseases that occur when there is an over-production of white blood cells known as histiocytes that can lead to organ damage and tumor formation in both children and adults. The only organization of its kind, HA works to encourage the patient and medical communities to improve and share knowledge of histiocytic disorders; provide critical emotional and educational support to patients and families; and identify and fund key research initiatives that lead to a world free of histiocytic disorders.

The Desmoid Tumor Research Foundation is the only foundation in the world dedicated to facilitating and funding research for a cure for desmoid tumors. The foundation funds research that uses cutting-edge science and creative clinical applications, as well as novel approaches that address potential leads based on prior research.

The Histiocytosis Association is a global nonprofit organization dedicated to addressing the unique needs of patients and families dealing with the effects of histiocytic disorders, a group of diseases that occur when there is an over-production of white blood cells known as histiocytes that can lead to organ damage and tumor formation in both children and adults. The only organization of its kind, HA works to encourage the patient and medical communities to improve and share knowledge of histiocytic disorders; provide critical emotional and educational support to patients and families; and identify and fund key research initiatives that lead to a world free of histiocytic disorders.

Objectives: The grant groundbreaking or unconventional methodologies, whose risky outlook is justified by the possibility of a major breakthrough. Basic Science: If a proposal is rooted in basic science, applicants are encouraged to collaborate with investigators who can further the potential for translation of ideas and findings. Translational Science: If a proposal is translational by nature, applicants are encouraged to identify industry and clinical partners to assist in propelling their research toward clinical study. Clinical Science: For those looking to submit a clinical research proposal, applicants are encouraged to collaborate with individuals who could facilitate potential clinical implementation.

The purpose of this Funding Opportunity Announcement (FOA) is to support milestone-driven projects focused on discovery, establishment of proof-of-concept for, and/or preclinical development of, lead candidate vaccines or immunoprophylactics that target multiple antimicrobial-resistant Gram-negative bacterial pathogens prevalent in nosocomial infections: carbapenem-resistant Enterobacteriaceae (CRE), multidrug-resistant (MDR) Acinetobacter and MDR Pseudomonas aeruginosa.

The NORD Research Grant Program provides seed-money grants to academic scientists for scientific and/or clinical research. The hope is that these studies will ultimately lead to new diagnostics, treatments, and/or cures for rare diseases. NORD's program provides grants for the study of diseases for which there are few other sources of funding. Grants provided through the NORD program are made possible by donations from individuals and organizations to restricted research funds at NORD.

The PCC has supported world-class research since 2008, spending more than $18.0 M to support novel science around the world. Research and grant-making are the foundation of the PCC and are the focus of everyday business activity. PCC-supported research contributes to a movement in addressing doping's root causes and ultimately decreasing the use of performance-enhancing drugs by all participants in all sports at all levels of play. Grant Cycle Deadlines: Pre-Applications are due March 1st, July 1st, and November 1st of each year. Applicants invited to submit full applications must do so by April 1st, August 1st, or December 1st, depending on the cycle (30 days after the pre-application due date). With an emphasis on original work that focuses on improving existing analytical methods for detecting particular drugs, developing new analytical methods to test for substances not currently detectable, and discovering cost-effective approaches for testing widely abused substances across all levels of sport, the following areas of investigation reflect the PCC's current research priorities: Developing methods of cost-effective testing to detect and deter the use of banned and illegal substances. Developing testing protocols to detect designer substances used for doping purposes. Improving existing analytical methods to detect particular drugs, ex. GH, IGF-1, EPO, hCG. Developing analytical methods to detect performance enhancing drugs not currently detectable. Longitudinal urinary excretion patterns, metabolism and dose-concentration. Critical reviews to support interpretation of laboratory data. Alternative specimens, (ex. oral fluid, dried blood/plasma spots) for testing. There is no maximum amount for PCC funding, though the average funding amount is $225,000. To date, over 80 projects have been funded in over 14 countries world-wide. Approximately 33% of applicants are awarded PCC funding.

The purpose of this Funding Opportunity Announcement (FOA) is to support milestone-driven projects focused on discovery, establishment of proof-of-concept for, and/or preclinical development of, lead candidate vaccines or immunoprophylactics that target multiple antimicrobial-resistant Gram-negative bacterial pathogens prevalent in nosocomial infections: carbapenem-resistant Enterobacteriaceae (CRE), multidrug-resistant (MDR) Acinetobacter and MDR Pseudomonas aeruginosa.

Applications to the Fiscal Year 2017 (FY17) Duchenne Muscular Dystrophy Research Program (DMDRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358). As directed by the Office of the Assistant Secretary of Defense for Health Affairs (OASD[HA]), the DHA manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The execution management agent for this Program Announcement is the Congressionally Directed Medical Research Programs (CDMRP). The DMDRP was initiated in 2011 to provide support for research of exceptional scientific merit and to promote the understanding, diagnosis, and treatment of Duchenne. Appropriations for the DMDRP from FY11 through FY16 totaled $20 million (M). The FY17 appropriation is $3.2M.

The DMDRP Career Development Award mechanism supports early-career investigators in conducting impactful Duchenne research under the mentorship of an experienced muscular dystrophy researcher as an opportunity to obtain the funding, mentoring, and experience necessary for productive, independent careers at the forefront of Duchenne research. Applicants should also demonstrate that the proposed research has high potential to lead to or make breakthroughs in Duchenne. Preliminary data are required.